Inactive Instrument

Analyst Reco. OptimizeRx Corporation Other OTC

Equities

US68401U1051

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

JMP Securities Initiates Coverage on OptimizeRx With Market Perform Rating, $15 Price Target	04-04	MT
RBC Adjusts OptimizeRx's Price Target to $17 From $14, Keeps Outperform Rating	01-10	MT
Barclays Starts OptimizeRx With Equalweight Rating, $15 Price Target	01-03	MT
Roth MKM Adjusts Price Target on OptimizeRx to $20 From $31, Maintains Buy Rating	15/08/23	MT
Lake street Adjusts OptimizeRx Price Target to $13 From $18, Maintains Buy Rating	15/08/23	MT
Stifel Adjusts Price Target on OptimizeRx to $13 From $16, Maintains Buy Rating	15/08/23	MT
B. Riley Cuts OptimizeRx's Price Target to $18 From $28 on Muted H2 Revenue Expectation, Keeps Buy Rating	15/08/23	MT
RBC Cuts Price Target on OptimizeRx to $14 From $18, Says 'Persisting Macro Headwinds Dampen' 2023 Outlook, Keeps Outperform Rating	15/08/23	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $28 From $30 After 'Slight' Q4 Miss, Keeps Buy Rating	09/03/23	MT
RBC Cuts Price Target on OptimizeRx to $18 From $22 After 'Disappointing' 2023 Guidance; Outperform Rating Kept	09/03/23	MT
B. Riley Resumes OptimizeRx at Buy With $30 PT, Notes Increased Pharma Ad Spend on Digital Channels as Key Market Tailwind	02/02/23	MT
Stifel Starts OptimizeRx at Buy With $19 Price Target	01/11/22	MT
B. Riley Securities Lowers OptimizeRx's Price Target to $37 from $56 After Lower-than-Expected Q2 Results, Keeps Buy Rating	10/08/22	MT
SVB Securities Adjusts OptimizeRx's Price Target to $30 from $38, Keeps Outperform Rating	10/08/22	MT
RBC Cuts Price Target on OptimizeRx to $22 From $50, Maintains Outperform Rating	10/08/22	MT
Piper Sandler Adjusts Price Target on OptimizeRx to $16 From $29, Maintains Neutral Rating	10/08/22	MT
B. Riley Lowers OptimizeRx's Price Target to $56 from $71, Says Consensus Estimates at Risk of Moving Lower into Q2 Print; Keeps Buy Rating	20/07/22	MT
SVB Securities Initiates OptimizeRx at Outperform With $38 Price Target	15/07/22	MT
Piper Sandler Initiates Coverage on OptimizeRx With Neutral Rating, $29 Price Target	01/07/22	MT
RBC Capital Adjusts Price Target on OptimizeRx to $50 From $100, Maintains Outperform Rating	05/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. OptimizeRx Corporation Other OTC

Equities

US68401U1051

Analyst Reco.

Filters